Its approach to buy-outs has helped Carlyle raise funds, since the same investor can put more money its way and still get the diversification he wants.
Along the way, for tax and supply diversification reasons, Bristol developed its own operation in Ireland to manufacture paclitaxel and then fired Hauser as a supplier.